SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after reporting robust earnings, driven by significant revenue growth and an improving path to profitability as its AI infrastructure expands. The community is actively discussing the company's substantial pipeline of new data center capacity, including advanced negotiations for 900MW across multiple hyperscale sites, anticipating strong long-term growth. This aggressive expansion into high-performance computing is fueling speculation about potential short-covering activity and a re-rating of the stock within the booming AI sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining significant attention after experiencing a substantial price surge on massive trading volume, which has triggered a technical breakout and suggests strong altcoin rotation. The community is actively discussing the potential for Jasmy to push past the one-cent threshold, fueled by anticipation of major 2026 developments focused on decentralized AI, data monetization, and its regulatory standing in Japan. While some voice skepticism about past volatility, many investors are highlighting its foundational utility in IoT and secure data, along with its ex-Sony leadership, as key drivers for future growth.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a notable multi-day decline, leading to discussions among the community about its deeply oversold technicals and a perceived lack of an immediate AI narrative compared to peers like Alphabet, which recently surpassed its market cap. While some express concern over the persistent weakness, many are actively buying the dip, anticipating a rebound and potential short squeeze dynamics fueled by unverified rumors of high synthetic short interest.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is trending after announcing positive FDA feedback, confirming its lead asset, sonelokimab, can proceed with a BLA submission for hidradenitis suppurativa without additional clinical trials. This regulatory clarity is widely seen as a significant de-risking event, fueling strong community speculation about a potential acquisition, particularly by Merck, at a substantial premium. Investors are actively discussing the company's long-term value and the cleared path to market for its inflammatory skin disease pipeline.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending after its preliminary Q4 results and future guidance projected a significant dip in DefenCath revenue due to anticipated reimbursement shifts, sparking a sharp sell-off and investor frustration. While many see the decline as an overreaction to a known temporary headwind, bullish voices emphasize compelling Real-World Evidence data for DefenCath's efficacy and the stock's deep undervaluation, noting strong institutional interest and future pipeline catalysts.

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

China SXT Pharmaceuticals Inc

China SXT Pharmaceuticals is trending due to its announced strategic AI insights initiative for traditional Chinese medicine, which has ignited significant price volatility. Community discussion highlights extreme intraday swings, with traders actively scalping and debating whether it's a high-risk "China pump and dump" or a legitimate runner. It is heavily watched within the broader "China play" theme, drawing comparisons to other recent low-float, high-volatility Chinese stocks experiencing rapid movements.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive (FLYX) is soaring amid news of its authorized dealership agreement with Starlink, positioning the company as an installer of high-speed in-flight internet for private jets and opening new MRO revenue opportunities. The community is actively discussing the potential for a massive short squeeze, driven by the stock's reportedly low float and explosive trading volume. Traders are eyeing significant upside, fueled by optimism around the SpaceX connection and comparisons to previous high-flying tickers.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is trending following news of significant year-over-year growth in Nociscan scan volumes, paired with a strong debt-free balance sheet and an extended cash runway. The community is actively debating the potential for a substantial short squeeze, driven by the company's tight share structure and perceived undervaluation, though some observers note its volatile history.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending as reports of potential U.S. government initiatives to boost the robotics sector, coupled with recent analyst upgrades, spark significant interest. The community is actively discussing the potential for a substantial short squeeze, fueled by unverified chatter of high synthetic short interest. This comes as the company rapidly expands its autonomous delivery fleet and strengthens key partnerships in the evolving "Physical AI" landscape for last-mile logistics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AdaptHealth ($AHCO) agreed to settle $51 million in cash and 1 million in shares with investors and $AHCO Call Option holders to end claims over overstating its organic growth trajectory.  
 
Who’s eligible?   
All persons who purchased or otherwise acquired AdaptHealth common stock or call options on AdaptHealth common stock or sold put options on AdaptHealth common stock during the period between November 8, 2019 and July 16, 2021, inclusive. 
   
Do I need to sell my shares to qualify?   
No — you are eligible whether you sold your shares or still hold them.   
   
How much is the payout?   
The payout per share is $0.63 — but if only ~25% of eligible investors file, the effective payout could increase.  
   
Can I still file?   
Yes — investors can still file a late claim to receive payment from the AdaptHealth settlement.  
   
When do payouts happen?   
Typically within 8–12 months after court approval of the settlement.   
   
To file your claim: https://11th.com/cases/adapthealth-investor-settlement

AdaptHealth (AHCO) agreed to settle $51 million in cash and 1 million in shares with investors and $AHCO Call Option holders to end claims over overstating i...

11th.com

AdaptHealth $AHCO (f/k/a DFB Healthcare) $51M + 1M Shares Settlement

StockTwits Web

AdaptHealth Corp

) agreed to settle $51 million in cash and 1 million in shares with investors and 

 Call Option holders to end claims over overstating its organic growth trajectory.  
 
Who’s eligible?   
All persons who purchased or otherwise acquired AdaptHealth common stock or call options on AdaptHealth common stock or sold put options on AdaptHealth common stock during the period between November 8, 2019 and July 16, 2021, inclusive. 
   
Do I need to sell my shares to qualify?   
No — you are eligible whether you sold your shares or still hold them.   
   
How much is the payout?   
The payout per share is $0.63 — but if only ~25% of eligible investors file, the effective payout could increase.  
   
Can I still file?   
Yes — investors can still file a late claim to receive payment from the AdaptHealth settlement.  
   
When do payouts happen?   
Typically within 8–12 months after court approval of the settlement.   
   
To file your claim: 

@11thestate   
 
Oh man.  I&#39;m not in this but the swing was much greater than $.63 to the downside in that period of time, so hopefully those holders are out by now.

   
 
Oh man.  I'm not in this but the swing was much greater than $.63 to the downside in that period of time, so hopefully those holders are out by now.